Drug Profile
Research programme: schizophrenia therapy - Galenea
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Galenea
- Class Small molecules
- Mechanism of Action Serotonin 2C receptor agonists; Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA
- 01 May 2012 Galenea receives funding from the Stanley Medical Research Institute for its pro-congnitine drug discovery programme